Case description
We report the clinical history of a boy, affected by early-onset epileptic encephalopathy with an episode of phenytoin neurotoxicity, found by whole exome sequencing to carry a previously undescribed mutation of the STXBP1 gene, combined with two heterozygous missense mutations in the same exon of the CYP2C9 gene.
A male, was born at 40 weeks by healthy non-consanguineous Italian parents after normal pregnancy; his body weight was 3.200 g. At 10 days, the child showed clonic movements of four limbs in clusters, sometimes prevailing on the right side, together with intense crying. Electroencephalography (EEG) recordings showed interictal spike and wave (SW) discharges over the left frontal and central areas and a widespread ictal SW discharge associated with bilateral clonic jerks. In the following weeks, clonic seizures manifested again several times a day with the same features. EEG recordings showed a suppression-burst pattern (Fig. 1A) . In the first month of life, both generalized and right sided tonic seizures frequently recurred, poorly responsive to phenobarbital therapy at the daily dose of up to 6 mg/kg with a serum level of 32 mcg/mL. Between 5 and 10 months of age, the child was seizure-free. At 14 months, seizures manifested again during sleep, fairly controlled by increasing the daily dose of carbamazepine up to 20 mg/kg and clobazam up to 1.5 mg/kg. At 3 years, frequent seizures recurred with deviation of the head and eyes to the right side, twitches of the eyelids, cyanosis of the face, followed by clonic jerks of the right upper limb, associated with EEG rhythmic theta activity over the left frontal-parietal regions. Seizures lasted less than 60 s. Then, the child had alternating periods of seizure worsening and improvement, and between 5 and 7 years, the interictal EEGs showed SW discharges over the right or both frontal regions. A first brain MRI was normal, but two further MRI studies, performed at 3 years and five months and 8 years of age showed a mild hyperintensity of the posterior periventricular and subcortical white matter, with a slight enlargement of lateral ventricles, making it hypothesize a genetic etiology more than a hypoxic-ischemic injury. Mutational scanning of SCN1A, UBE3A, MECP2, CDKL5 genes and CGH-array and FISH analysis of the 15q11.3-13 region were negative. The child presented hypotonic quadriplegia with postural instability, progressive scoliosis and intentional tremor. Speech was absent. From 7 years to follow-up, clusters of tonic-vibratory seizures, lasting no more than 10 s recurred mainly during sleep. Video-EEG recordings showed recurring episodes during sleep characterized by sudden eyes opening, light flexion of the head, fixed staring for about 10 s associated with a stereotypical EEG pattern (Fig. 1B) . Because of seizure persistence, phenytoin (PHT) was added to background therapy consisting of topiramate (3 mg/kg/24 h) and clobazam (1 mg/kg/24 h), initially at 0.5 mg/kg followed by increments of 0.5 mg/kg each 5 days, up to 2.6 mg/kg/day after 2 weeks. The child showed marked lethargy and coma and plasma PHT levels showed unexpected values of 23.1 mg/mL. At this time, whole metabolic work-up including serum acid-base balance, ammonium, lactate, creatinine and liver function, was normal. Phenytoin was thus discontinued and the patient quickly recovered. Between 8 and 11 years of age, there were alternating periods of seizure frequency increase (1-12 episodes/daily, mainly during sleep), and clinical improvement. At age 13 years, the child shows severe intellectual disability with aphasia and dystonic quadriplegia.
Whole exome sequencing, performed as described by [1] (see Supplementary material for details) revealed a new heterozygous mutation in intron 6 of STXBP1 gene (RefSeq NM003165, c.430-1delT_-2insTTGG) causing loss of the splicing acceptor site and consequent exon 7 skipping, resulting in a truncated protein lacking the Sec-1-like domain 2 with the introduction of a stop codon after 19 amino acids (Fig. 1C) . STXBP1 (9q34), encoding the syntaxin binding protein 1/Munc18.1, plays a major role in the fusion of secretory vesicles to the presynaptic membrane, allowing release of neurotransmitters into the synaptic cleft. Mutations of the STXBP1 gene cause disruption in protein synthesis/degradation, leading to detrimental effects in neurotransmitter release, have been implicated in early onset epileptic encephalopathy with suppression bursts (EESB), infantile spasms (IS), unclassified early-onset epileptic enceph- alopathies (EOEE) and non syndromic mental retardation (MR) [2] . A complete classification of the STXBP1 mutations reported is reported in Table 1 (Supplementary material) with the main clinical features at onset.
Interestingly, the same patient carried also a heterozygous missense mutation in CYP2C9 (c.882G > T, p.L294F, rs544027339) and an additional one in the same exon of this gene (c.920G > A, p.R307K), not previously described. Functional prediction indicates that both these mutations are likely to interfere with enzyme activity (Fig. 1D ). CYP2C9 is a major cytochrome enzyme involved in the metabolic clearance of a wide variety of therapeutic agents, including anticonvulsants such as PHT and, phenobarbital.CYP2C9 is responsible for the metabolic clearance of up to 15% of all drugs that undergo Phase I metabolism [3] . CYP2C9 defects have been implicated in phenytoin adverse reactions, and patients treated with PHT could benefit from CYP2C9 and CYP2C19 genotyping [4] . CYP2C9 variations found in our patient could thus correlate with the severe adverse reaction to phenytoin titration, leading to lethargy and coma. PHT has a narrow therapeutic window (10-20 mg/mL) and adverse drug reactions become common with levels >10 mL/mL, with remarkable, dose-dependent neurological side effects. A further rise in drug levels may lead to cerebellar atrophy, lethargy, coma, and even precipitate status epilepticus.
To the best of our knowledge, there are no previous report on the co-occurrence of mutations in the STXBP1 gene and variants of the CYP2C9 gene. This may be in part explained by the fact that most of the reported cases with STXBP1 mutations have been identified by sequencing focused on this single gene, instead of the whole exome sequencing approach applied here, that allowed identification of a new STXBP1 mutation in this severe epileptic encephalopathy coexisting with a compound heterozygosity in the CYP2C9 gene that helps explain the serious PHT neurotoxicity that occurred in this child.
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